CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress

Reuters

2025/10/06

CARsgen <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress

CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology $(ASH)$ in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573644149"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573644149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573644149?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573644149","market":"nz","top_or_hot":-1,"title":"CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLc9kmnx:1","article_id":"2573644149","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573644149","pubTimestamp":1759709175,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1585":"昨日强势股","BK1587":"次新股","02171":"科济药业-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"科济康将在ASH 2025年年会上展示同种异体BCMA CAR-T疗法CT0596的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9},"content_text":"CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    \n\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology $(ASH)$ in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}